Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (April 2022)
16 slides from Oncosil Medical's investor presentation, Apr 29, 2022
Slide 1: Investor presentation 29 April 2022
For personal use only Investor presentation 29 April 2022
Slide 2: OncoSil Medical's targeted approach to pancreatic cancer treatment
For personal use only OncoSil Medical’s targeted approach will deliver a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients 2 • Investor Presentation • 29 April 2022
Slide 3: Executive Summary
Executive Summary For personal use only OncoSil™ is a commercial-stage • Implanted device delivers targeted radiation to pancreatic tumour breakthrough device delivering targeted radiotherapy for pancreatic cancer • Breakthrough designation received in the EU/UK, US and Singapore • Experienced manag
Slide 4: OncoSil Device Overview
OncoSil™ Device Overview For personal use only OncoSil™ is intended OncoSil™ is for the treatment of implanted directly locally advanced into a pancreatic tumour unresectable via injection under pancreatic cancer, endoscopic in combination with 98% ultrasound of all gemcitabine-based guidance radiat
Slide 5: Management Team with a Depth of Experience and Expertise
Management Team with a Depth of Experience and Expertise For personal use only Nigel Dr Jon David Henk Lange Bell MD Turner Tissing Managing Chief Medical Head of Director of Clinical Director & CEO Officer Medical Affairs Development 30+ years 25+ years 8+ years experience as industry experience in
Slide 6: PanCO study demonstrated positive safety and efficacy signals
PanCO study demonstrated positive safety and efficacy signals For personal use only Of the many encouraging outcomes from the PanCO study1, four are particularly important: Established safety profile: No evidence suggesting any additional risk from using OncoSil™ 90.5% of OncoSil™ treated patients h
Slide 7: PanCO results showing compelling evidence of downstaging
PanCO results showing compelling evidence of downstaging OncoSil™ converted patients with unresectable locally advanced pancreatic cancer (LAPC) For personal use only to surgically resectable, transforming their prognosis and substantially extending survival Why is resection What did the PanCO study
Slide 8: What we have accomplished
What we have accomplished For personal use only Experienced CE Marking Innovation Funding Enabled HDE pathway team in place obtained (NUB) approved for bile duct cancer German funding in US enabled of the OncoSil™ device Application submitted to FDA PanCO Study Breakthrough device Current market app
Slide 9: Strong team in place to lead commercial activities
Strong team in place to lead commercial activities For personal use only Germany All team members have extensive Dr. Frank Müller prior experience in specialist Regional Head DACH 23 years oncological application of Christine Gold Sr. Key Account Mgr. radioisotopes at large medical 22 years device c
Slide 10: Sales and training activities to date
Sales and training activities to date During the pandemic, the OncoSil™ team worked to For personal use only achieve sales-readiness with key start-up activities Key experienced sales, marketing and training team in place – no need for any expansion of the team in the near term Distributors have bee
Slide 11: This is where we are today
This is where we are today Market access and clinical development supporting sales activities For personal use only Sales team fully engaged with targeted Key Opinion Leaders to improve knowledge base of OncoSil ™ technology. • Face to face meetings now in place following COVID-19 access restriction
Slide 12: Innovation Funding (NUB) in Germany
Innovation Funding (NUB) in Germany Funding for the use of the OncoSil™ device in Europe’s largest market For personal use only In February 2022, the Institute for the Hospitals who have submitted NUB applications Hospital Remuneration System (InEK) can now negotiate with Statutory Health Insurance
Slide 13: G-BA Fully Funded trial in Germany
G-BA Fully Funded trial in Germany Fully-funded trial leading to public insurance reimbursement For personal use only In March 2022, the Federal Join Committee (G-BA) recommended a fully- OncoSil will receive revenue payments for the funded trial take place in Germany provision of the OncoSilTM devi
Slide 14: This is where we intend to go: Commercial Vision in 2022
This is where we intend to go Commercial Vision in 2022 For personal use only Fully funded Submission of Commencement Insurance Signing of manuscript Reach consensus with government of commercial reimbursement in distribution on surgical FDA on pivotal study sponsored clinical sales in Spain the UK
Slide 15: Disclaimer
Disclaimer For personal use only This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Present
Slide 16: Nigel Lange, CEO & Managing Director
For personal use only Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com OncoSil Medical Ltd www.oncosil.com T: +49 30 300 149 3043